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Abstract: Reference hemoglobin (Hb) values for the definition of anemia are still largely 
based on the 1968 WHO Scientific Group report, which established a cutoff value of <13 g/dL 
for adult men and <12 g/dL for adult nonpregnant women. Subsequent studies identified dif-
ferent normal values according to race and age. Estimated prevalence of anemia on admission 
in the setting of an acute coronary syndrome (ACS) is between 10% and 43% of the patients 
depending upon the specific population under investigation. Furthermore, up to 57% of ACS 
patients may develop hospital-acquired anemia (HAA). Both anemia on admission and HAA are 
associated with worse short- and long-term mortality, even if different mechanisms contribute 
to their prognostic impact. Baseline anemia can usually be traced back to preexisting disease 
that should be specifically investigated and corrected whenever possible. HAA is associated 
with clinical characteristics, medical therapy and interventional procedures, all eliciting car-
diovascular adaptive response that can potentially worsen myocardial ischemia. The intrinsic 
fragility of anemic patients may limit aggressive medical and interventional therapy due to an 
increased risk of bleeding, and could independently contribute to worse outcome. However, 
primary angioplasty for ST elevation ACS should not be delayed because of preexisting (and 
often not diagnosed) anemia; delaying revascularization to allow fast-track anemia diagnosis 
is usually feasible and justified in non-ST-elevation ACS. Besides identification and treatment 
of the underlying causes of anemia, the only readily available means to reverse anemia is red 
blood cell transfusion. The adequate transfusion threshold is still being debated, although solid 
evidence suggests reserving red blood cell transfusions for patients with Hb level <8 g/dL and 
considering it in selected cases with Hb levels of between 8 and 10 g/dL. No evidence supports 
the use of iron supplements and erythropoiesis-stimulating agents in the setting of ACS.
Keywords: anemia, acute coronary syndrome, hemoglobin, red blood cell transfusion
Introduction
Anemia in the setting of acute coronary syndrome (ACS) has an established adverse 
prognostic value. Its impact on outcome appears to be independent of underlying 
causative factors – most often multiple – and time of onset, either it being preexisting 
the ACS or developing during hospitalization or at follow-up. In both settings, anemia 
has been shown to be an independent predictor of short- and long-term mortality.1–13
However, anemia must be put in perspective, keeping in mind that the main role of 
hemoglobin (Hb) is to provide adequate oxygen supply to body tissues. Therefore, its 
concentration in blood will vary according to body mass, with resultant physiological 
lower levels in most women.1,2 As shown in Figure 1, when considering overt anemia, 
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3 main determinants need to be considered: adequate 
erythro poiesis – that is, bone marrow function and adequate 
 production of the specific growth factor; erythropoietin – that 
is, renal function – and preserved red blood cell (RBC) mass-
to-plasma volume ratio – that is, hemodilution.3–8
All these pathogenetic determinants may be deranged in 
patients with ischemic heart disease, leading to abnormali-
ties in Hb levels. Addressing the mechanism(s) underlying 
the development of anemia in a specific patient may help to 
correct anemia, and possibly overcome or lessen its negative 
prognostic impact in the setting of ACS (Figure 2).
The aim of this article is to present an overview of cur-
rent evidence regarding epidemiology, pathophysiology, 
prognostic role and therapeutic management of anemia in 
patients with ACS.
Definition of anemia and clinical 
determinants of Hb levels
Anemia is accurately defined as an absolute decrease in RBC 
mass as determined by radiolabeled blood volume analysis.14 
However, the definition adopted in clinical practice com-
monly refers to the derived parameters, Hb and hematocrit 
(Hct).
Reference Hb values for the definition of anemia are still 
largely based on the 1968 WHO Scientific Group report, 
which established an Hb cutoff value of <13 g/dL for adult 
men and <12 g/dL for adult nonpregnant women.15 This 
definition is more a derivative of normal distribution of Hb 
concentrations and observed SDs from “average”, which is 
assumed to be the same as “normal”. More recently, several 
research groups tried to redefine anemia taking into account 
clinical variables in order to give more accurate estimates of 
normal values.
In 2006, a new cutoff for anemia was suggested by Beutler 
and Waalen16 based on 2 large databases: the NHANES-III, 
the third US National Health and Nutrition Examination 
Survey, and the Scripps–Kaiser survey conducted in the 
San Diego area between 1998 and 2002. In these analyses, 
normal Hb levels were set taking into account not only sex 
but also race and age. Results showed that people of African 
ancestry have at least 0.5 g/dL lower Hb levels compared to 
Caucasians, and people >60 years of age have lower Hb levels 
compared with younger adults.16
The role of age in determining Hb levels was confirmed 
in 2008 by Patel et al who demonstrated that the mean Hb 
concentration in men was lower and variance was greater with 
each ascending age group from 50 to >80 years.17 The reasons 
of this variability reside in some specific characteristics of 
older adults, summarized in Table 1.
Our group specifically addressed the issue of anemia in 
elderly patients hospitalized for ACS.18 Anemia is especially 
frequent in this specific patient population, being detected 
in up to 43% of elderly patients admitted for acute heart 
disease,19 and its independent adverse prognostic impact 
is well recognized.20 Our analysis was specifically aimed 
at assessing the role of 2 common conditions known to be 
Determinants of basal
hemoglobin concentration
Age Gender BMI
Determinants of anemia
AltitudeRace
Genetic
determinants
•  Increased plasma volume relative to
   erythrocyte mass, hemodilution
   (i.e., fluid overload, 
   splenomegaly, pregnancy)
•  Decreased erythropoietin production
   (i.e., advanced renal failure, inflammatory
   conditions anemia of chronic disease)
•  Bone marrow failure
   (i.e., vitamin and iron deficiency, hemoglobin
   synthesis disorders, primitive bone marrow
   disorder, uncompensated hemolytic anemias)
Figure 1 Determinants of anemia.
Abbreviation: BMI, body mass index. 
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results demonstrated that the relationship between anemia 
and age per se or estimated glomerular filtration rate or BMI 
was weak. These results stress the concept that physiological 
lowering of Hb levels does not necessarily translate into overt 
anemia. When present, even in elderly subjects with multiple 
comorbidities, anemia should be viewed as a marker of an 
underlying disease state and should be specifically investi-
gated as such and corrected whenever possible.18
Hemodilution is an additional, and often overlooked, 
confounding determinant of decreased Hb levels in patients 
affected by ACS and concomitant heart failure. Heart failure 
leads to chronic fluid overload and may be associated with 
splenomegaly of varying degrees. Extent of fluid overload 
is difficult to be precisely estimated based solely on clini-
cal evaluation. Very few studies addressed the issue of fluid 
overload in patients with advanced heart failure. However, 
when more accurate measurement of RBC mass relative to 
plasma volume using I131-tagged albumin was performed, 
Table 1 Characteristics related to anemia in the elderly
•	 Sarcopenia: the reduced muscle mass lowers the peripheral oxygen 
demand and, therefore, causes a physiologic reduction in circulating 
blood mass
•	 Stem cell alteration: older patients normally have lower cellular bone 
marrow and hematopoietic colony-forming unit
•	 Different hormone levels (mainly sex hormone)
•	 Reduced erythropoietin induction secondary to hypoxia related to renal 
disfunction
•	 Impaired inflammatory answer: the slowdown catabolism of cytokine 
and minor anti-inflammatory action of sex hormone induce an 
extension of inflammatory answer also after the stimulus removal
Trigger:
Hypoxia
Trigger:
Hypoxia
Trigger:
Baroreceptor
Objective:
Maintain circulatory
volume
Mechanism:
•  Peripheral
   vasoconstriction
•  Renal sodium
   retention
•  Cardiac output/heart
   rate increase
Mechanism:
•  Increased heart rate
•  Changes in the Hb-
   oxygen dissociation
   curve
•  Increased
   erythropoietin
   release
Mechanism:
•  Peripheral
   vasodilatation
•  Changes in the Hb–
   oxygen dissociation
   curve
•  Increased
   erythropoietin release
There are neither
compensatory nor cardiac
or renal mechanisms
Associated to
immunoflogosisObjective:
Increase oxygen
delivery
Objective:
Increase oxygen
delivery
Anemia-induced compensatory mechanisms
Hypovolemic acute anemia
(i.e., hemorrhage)
Normovolemic acute
anemia
(i.e., autoimmune hemolytic
anemia)
Chronic anemia
Figure 2 Anemia-induced compensatory mechanisms.
associated with lower Hb levels: impaired renal function and 
body mass index (BMI) as surrogate markers for sarcopenia. 
An elderly population (aged ≥75 years) admitted for non-ST 
elevation ACS (NSTEACS) and enrolled in the prospective 
Italian Elderly ACS study was analyzed. Although anemia 
was confirmed to be an independent predictor of mortality, 
even after adjustment for the most relevant covariates, our 
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the low Hb levels turned out to be linked to fluid overload in 
40%–46% of patients.14,21
Anemia and ACS: epidemiology and 
prognostic impact
Anemia on admission
Several studies addressed the prevalence of anemia on 
admission in the setting of ACS,1–8,18 with estimates varying 
between 10% and 43% as summarized in Table 2.
Differences in prevalence can be traced back to multiple 
factors related to the specific population analyzed. For 
example, the prevalence of anemia is higher in patients from 
the Middle East where disorders of Hb synthesis are more 
frequently found.6 Nutritional deficits may also account 
for higher prevalence rates.6 As already mentioned, studies 
focusing on elderly patients usually report the highest figures.
In both randomized trials and meta-analyses, anemia on 
admission is always related to worse outcome, being associ-
ated with increased mortality at different observation time 
points, as summarized in Table 3.3–6,8,9,18
Hospital-acquired anemia (HAA)
HAA, defined as development of new anemia developing 
during hospitalization, is often observed in patients admit-
ted for an ACS.
In the study by Salisbury et al,10 the prevalence of HAA 
was investigated in a cohort of 17,676 patients with acute 
myocardial infarction and normal admission Hb. Applying the 
age-, sex- and race-specific criteria described by Beutler and 
Waalen,16 HAA was diagnosed in those patients whose nadir 
Hb level fell during hospitalization below the set diagnostic 
threshold for anemia. Overall prevalence of HAA was 57%, 
with mild (Hb >11 g/dL), moderate (Hb 9–11 g/dL) and 
severe HAA (Hb <9 g/dL) accounting for 37%, 15% and 5% 
of patients, respectively. The presence and severity of HAA 
were associated with most of the clinical characteristics also 
associated with anemia on admission, namely, age, female 
sex, history of cardiovascular risk factors and chronic kidney 
disease. Cardiogenic shock, acute renal failure and exten-
sive use of antiplatelet and anticoagulation therapies were 
identified as additional, in-hospital determinants of HAA. 
In-hospital mortality rates differed according to the severity 
of HAA, with higher rates being observed in patients with 
either mild moderate (adjusted odds ratio [OR] 1.38, 95% 
CI: 1.10–1.73) or severe HAA (adjusted OR 3.39, 95% CI: 
2.59–4.44) compared with not anemic patients.10
HAA has also been associated with long-term outcome. 
Results in smaller cohorts of patients linked the highest 
in-hospital Hb drop to worse 6-month outcome in terms 
of mortality (adjusted HR of 1.83%, 95% CI: 1.08–3.11, 
p=0.026) and death/myocardial infarction (adjusted HR 
1.6%, 95% CI: 1.04–2.44, p=0.031).11 One-year mortality 
and cardiovascular morbidity were also higher (HR 2.47, 
95% CI: 1.23–4.96, p=0.01).12
HAA that does not resolve after discharge may have 
adverse long-term prognostic implications. In a group of 
1065 patients studied by Hasin et al,13 anemia of any sever-
ity was present at discharge in 35% of cases. At a median 
follow-up of 27 months (range 12–44 months), the authors 
found that anemia had resolved in 15% of the patients and 
persisted in 19%. In 5% of the patients, new-onset anemia 
(defined as an Hb decrease of at least 0.5 g/dL compared to 
hospital discharge values) developed. Long-term outcome, 
defined as all-cause mortality and rehospitalization for acute 
heart failure, of those patients whose HAA resolved over 
time was similar to that of patients who were not anemic 
(HR 0.8, 95% CI: 0.5–1.3). Conversely, the event rates were 
markedly increased in those patients with either persistent 
(HR 1.8, 95% CI: 1.2–2.5) or new-onset (HR 1.9, 95% CI: 
1.1–3.3) anemia.13
Table 2 Prevalence of baseline anemia in ACS studies
Authors, year N Population Nation, special note Prevalence
Wu et al,1 2001 78,974 AMI, ≥65 years old USA 43.4%
Archbold et al,2 2006 2310 ACS UK 29.7% women
23.2% men
Meneveau et al,3 2009 1410 ACS France 27%
Tsujita et al,4 2010 3153 STEACS Multinational 10.5%
Sulaiman et al,5 2011 7922 ACS Middle East countries 28%
Kunadian et al,6 2014 13,032 NSTEACS Multinational 16.9%
Shiraishi et al,7 2014 1447 Primary PCI in AMI Japan 25.8%
Morici et al,18 2014 637 NSTEACS, ≥75 years old Italy 37.7%
Yazji et al,8 2017 1731 ACS UK 26.9%
Abbreviations: ACS, acute coronary syndrome; AMI, acute myocardial infarction; N, number of in-study patients; NSTEACS, non-ST-elevation acute coronary syndrome; 
PCI, percutaneous coronary intervention; STEACS, ST-elevation acute coronary syndrome.
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Prognostic impact of anemia in 
ACS: a pathophysiologic prospective
In the majority of patients with heart disease, anemia of chronic 
disease (ACD) is diagnosed. ACD is associated with a number 
of conditions characterized by acute or chronic immune activa-
tion,22 including heart disease, and it has also been referred to 
as “anemia of inflammation”.23 This specific entity should be 
viewed as part of the systemic inflammatory response syndrome, 
a first-line defensive strategy phylogenetically developed to 
fight microbial infections. Iron increases the virulence of most 
pathogens,24,25 and the release of acute-phase cytokines (tumor 
necrosis factor α, interleukin (IL)-1, IL-6) is associated with 
reduced iron availability and iron-restricted hemopoiesis,23 as 
shown in Table 4. In a way, anemia associated with the systemic 
inflammatory response syndrome can be envisioned as the price 
the organism has to pay to better face infection. However, if not 
associated with other aggravating cofactors and being part of 
a protective defense strategy, ACD is seldom severe and detri-
mental to the organism. In this perspective, the mild anemia so 
often found in ischemic heart disease patients may not represent 
a negative prognostic marker per se. Conversely, it might be 
viewed as a marker of a preexisting, systemic underlying disease 
state defining a “more fragile” patient.
In a recent survey, Mamas et al examined the correlates 
and associations between anemia and subsequent cardio-
vascular risk in a large retrospective cohort of patients 
presenting with ACS and found that patients with anemia 
had more comorbidities compared with their counterparts 
with normal Hb levels. Moreover, several preexisting factors 
were independently associated with anemia: smoking, hyper-
lipidemia, angina, previous myocardial infarction, previous 
heart failure, previous stroke, peripheral vascular disease, 
Table 3 Outcome related to baseline anemia in ACS studies 
Authors, year N Population Outcome Investigation time Risk (95% CI)
Meneveau et al,3 
2009
1410 ACS Mortality In-hospital
30 days
HR 2.1
HR 2.3
Tsujita et al,4 2010 3153 STEACS All-cause mortality 1 year HR 1.98 (1.05–3.73)
Major bleeding 1 year HR 2.15 (1.43–3.24)
Sulaiman et al,5 2011 7922 ACS Mortality In-hospital
30 days
1-year
OR 1.71 (1.34–2.17)
OR 1.34 (1.06–1.71)
OR 1.22 (1.01–1.49)
Kunadian et al,6 2014 13,032 NSTEACS Composite 
ischemic event
In-hospital
30 days
1 year
RR 1.39 (1.17–1.67)
RR 1.40 (1.20–1.62)
RR 1.48 (1.33–1.64)
HR 1.23 (1.05–1.44)
Mortality In-hospital
30 days
1 year
RR 2.07 (1.31–3.26)
RR 2.23 (1.64–3.02)
RR 2.35 (1.94–2.84)
HR 1.77 (1.29–2.44)
Major bleeding In-hospital
30 days
RR 2.20 (1.84–2.64)
RR 2.30 (1.94–2.73)
Morici et al,18 2014 637 NSTEACS, 
≥75 years old
Mortality 1 year HR 1.72 (1.14–2.60) for Hb 10–13 g/dL
HR 2.50 (1.35–4.57) for Hb < 10 g/dL
Yazji et al,8 2017 1731 ACS Mortality 1 year OR 2.42 (1.40–4.16)
Lawler et al,9 2013 233,144 ACS Mortality In-hospital
30 days
1 year
Maximum (mean 18 months)
RR 2.76 (1.94–3.92)
RR 2.81 (1.91–4.14) HR 1.75 (1.02–3.01)
RR 1.69 (1.17–2.43)
HR 1.63 (1.10–2.40)
RR 2.08 (1.70–2.55) HR 1.49 (1.23–1.81)
Re-infarction Maximum (mean 18 months) RR 1.25 (0.78–2.02)
Abbreviations: ACS, acute coronary syndrome; HR, hazard ratio; N, number of in-study patients; NSTEACS, non-ST-elevation acute coronary syndrome; OR, odds ratio; 
RR, relative risk; STEACS, ST-elevation acute coronary syndrome.
Table 4 Effects of inflammatory response mediated by cytokines 
(IL-1, IL-6, TNFα, IFNγ, TGFβ)
•	 Shorter half-life of red blood cells
•	Antiproliferative action against endothelial progenitor cells
•	 Low iron availability for emopoiesis
•	Reducted erithropoietin productiosn
•	Minor response of hematopoietic progenitors to stem cell factor and 
EPO for receptor downregulation
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diabetes mellitus, chronic obstructive pulmonary disease, 
renal disease and previous coronary intervention.26
A role for the systemic inflammatory response syndrome 
has been suggested also in reducing the capacity for vascular 
healing. Solomon et al found decreased levels of peripheral 
circulating endothelial progenitor cells in ACS patients 
affected by anemia on admission compared to non-anemic 
subjects. They hypothesize that, in addition to a preexisting 
inflammatory condition, the systemic effects of the inflam-
matory response induced by myocardial necrosis are not just 
limited to blunted erythroid function but also involve the 
ability to produce or mobilize endothelial progenitor cells by 
the bone marrow. This, in turn, may compromise the vascular 
healing capacity and contribute to poor prognosis of patients 
with ACS and anemia.27
Anemia has been linked to worse prognosis in a number 
of different clinical settings. While it is still unclear whether 
mild anemia directly leads to poor outcomes, it is reasonable 
to hypothesize that it may reflect a more severe underlying 
systemic illness.28
Prognostic impact of anemia in 
ACS: the role of suboptimal 
treatment
Aside from pathophysiological considerations, anemia may 
impact on the outcome because anemic patients may not 
receive guideline-recommended treatment for ACS.
This data has emerged from the Biennial Israeli ACS 
registry (ACSIS) which prospectively enrolled 5600 patients 
with ACS. Because of a perceived increased hemorrhagic 
risk, coronary angiography was performed less frequently in 
patients with anemia compared with patients without anemia 
(77% vs. 91%, p<0.001). Among patients with anemia who 
underwent coronary angiography, the majority (95%) had 
obstructive coronary disease, and 78% of them were triaged 
to revascularization. Among anemic patients, an invasive 
approach was associated with lower mortality at 30 days 
and at 1 year, with no significant excess in major bleed-
ing.29 Indeed, in-hospital bleeding complications have been 
reduced by the almost universal use of the radial percutaneous 
approach to coronary intervention, as well as more selective 
use of GPIIb/IIIa receptor blockers and heparins.30
The lack of clarity in contemporary guideline recom-
mendations as to how patients with anemia should be treated 
has also affected post-discharge treatment.
In a retrospective cohort of 422,855 patients with ACS 
enrolled between January 2006 and December 2010 in the 
UK, similar rates of angiography were observed in the anemic 
vs. non-anemic patients. However, anemic patients were sig-
nificantly less likely to be prescribed secondary prevention 
medications. In this large cohort study, the impact of anemia 
on mortality was independent and almost comparable across 
the ACS spectrum.26
Anemia and ACS: to treat or not to 
treat?
In the complex scenario of ACS, the balance between risks 
and benefits of RBC transfusion is likely to be influenced by 
multiple factors. From a theoretical point of view, transfusing 
RBC increases oxygen delivery to the vulnerable myocar-
dium, reducing ischemic symptoms, but few confirmatory 
data exist.31
However, the ability of transfused RBC to increase oxy-
gen delivery may be reduced because of rapid depletion of 
red cell nitric oxide content during storage.32 Moreover, while 
the goal of RBC transfusions is to increase the oxygen trans-
port (CaO
2
) and oxygen delivery (DO
2
), the corresponding 
increase of Hct results in increased blood viscosity which, 
in turn, decreases blood flow and reduces DO
2
. Therefore, 
increasing the Hct in anemia may not correspondingly 
increase DO
2
.33 RBC transfusion-related adverse events may 
also hamper clinical benefits, with special regard to the so-
called not infectious serious hazards of transfusion, which 
include transfusion-related circulatory overload and, among 
immune-mediated adverse reactions, transfusion-related 
acute lung injury.34 A role of RBC transfusion in increasing 
systemic inflammation and erythrocyte slugging in capillary 
vessels has also been hypothesized.35
Whereas the high prevalence and adverse prognostic 
impact of anemia in patients with ischemic heart disease are 
recognized, whether it deserves treatment and at which Hb cut-
off level treatment needs to be implemented are still a matter 
of debate. This is especially true when anemia is part of the 
systemic inflammatory response syndrome, which is usually 
seldom associated with severely decreased Hb concentration.
Even if anemia results from reversible conditions, for 
example, vitamin or iron deficiencies and immune-mediated 
hemolysis, days to weeks are usually necessary for its resolu-
tion. Therefore, the only readily available treatment is RBC 
transfusion.
Transfusion has an established role in the setting of acute 
anemia, whereas its role in chronic anemia, especially of 
mild degree, is still controversial. A number of studies have 
focused on which Hb and/or Hct level should be considered 
the “adequate transfusion threshold” in critically ill patients 
or in patients undergoing surgery.36,37
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The debate has centered on 2 distinct transfusion strate-
gies: one is to consider a restrictive threshold, that is, trans-
fusion not indicated until Hb level <7–8 g/dL, and the other 
is to adopt a more liberal threshold, that is, transfusion not 
indicated until Hb level <9–10 g/dL. Most data are derived 
from studies including a mixed population of intensive care 
unit (ICU) severely ill patients, including those with cardiac 
disease.
In 1999, Hebert et al published the results of TRICC 
trial, a multicenter randomized controlled clinical trial that 
compared the 30-day mortality among 838 ICU critically ill 
patients receiving RBC transfusion according to a restrictive 
or a liberal strategy. The outcome was similar in the 2 groups. 
However, the restrictive strategy yielded significantly better 
results in patients younger than 55 years and in less acutely 
ill patients without ACS. An analysis of the subgroup with 
preexisting ischemic heart disease yielded opposite results, 
with higher mortality rates among those patients managed 
according to the restrictive strategy (26% vs. 21%, p-value 
0.03).38
Deans et al reported a commentary about the previous 
study, its design and results: although the randomization to 
2 relatively fixed treatment protocols was the chosen design 
for simplicity and power, this approach could represent a 
“practice misalignment” because it applied the fixed thera-
peutic regimens typical of a clinical trial in a therapeutic area 
where treatment should be rather influenced by a patient’s 
characteristics and comorbidities. Indeed, the overall out-
comes may be influenced by a single misaligned subgroup 
if patients affected by ischemic heart disease, who would be 
usually transfused to maintain higher Hb values, were ran-
domized to the restrictive strategy, and younger and healthier 
subjects received relative large volumes of RBC. Therefore, 
these authors suggest developing trial designs that stratify 
patients into comparable subgroups to help minimize the 
practice misalignments.39
Clinical outcomes according to 2 transfusion strategies 
were reviewed also by Carson et al in a meta-analysis of 
>12,500 patients enrolled in clinical trials conducted in sur-
gery and ICU subjects. The results were similar to those of the 
TRICC trial: compared to a liberal strategy, the restrictive one 
was associated with lower rates of multiple adverse clinical 
outcomes, including 30-day mortality, myocardial infarction, 
cerebrovascular accident, recurrent bleeding, pneumonia or 
thromboembolism.40
Data on the association between blood transfusion need 
and outcome in European ICU patients were obtained from the 
SOAP study. In this prospective, multicenter, observational 
study, 33% of patients received RBC transfusions (mean of 
transfused units ±SD: 5.0±5.8). These patients were older, 
were more severely ill at admission (according to SAPS II 
and SOFA score), had longer duration ICU stays and had 
higher ICU mortality rates. Although there was a direct 
relation between the number of blood transfusions and the 
mortality rate, in a multivariate Cox regression analysis 
including the main confounding factors (sex, age, type of 
admission, medical history, fluid balance, SOFA score and 
SAPS II), transfused patients did not have 30-day mortality 
rates higher than those who were not transfused.41 This con-
cept was resumed in the related commentary: “the sicker the 
patient, the more likely the transfusions will be beneficial”.42
In the setting of moderate-high risk (EuroScore ≥6) 
cardiac surgery, Mazer et al recently compared transfusion 
strategies in 4806 patients. According to their data, the restric-
tive strategy was non-inferior to the liberal one with respect 
to the composite outcome of death and major disability 
(myocardial infarction, stroke or new-onset renal failure with 
dialysis). Although no significant differences were identified 
among the various types of cardiac procedures, the group of 
patients subjected to only-CABG intervention (26%) showed 
an advantage with the liberal approach (unadjusted OR 1.18, 
95% CI: 0.79–1.75).43
A limited number of studies focused on the prognostic 
impact of RBC transfusion in ACS patients,44–47 and results 
are not uniform also in this setting.
In 2016, Docherty et al published a systematic review 
and meta-analysis aimed at assessing clinical outcomes for 
patients affected by cardiovascular disease managed with 
restrictive or liberal transfusions. Data were derived from 
11 randomized trials enrolling 3033 patients for 30-day 
 mortality and from 9 trials with 2609 patients for new 
cardiovascular events. A restrictive transfusion threshold 
was associated with an increased risk of ACS in patients 
with cardiovascular disease: (59 events/1319 patients vs. 
32 events/1290 patients; risk ratio 1.78, 95% CI: 1.18–2.70, 
p=0.01, I²=0% for restrictive transfusion). This corresponds 
to 4.6 episodes of ACS per 100 patients when using restric-
tive strategies and 2.7 episodes per 100 patients when using 
liberal strategies. On the other end, the length of hospital 
stay did not differ between restrictive and liberal transfusion 
strategies, and no difference was observed in 30-day mortality 
between the 2 groups.44
According to the meta-analysis by Chatterjee et al that 
included more than 203,600 ACS patients, RBC transfusion 
was associated with an increase in all-cause mortality and 
recurrent infarction.45 Similar results were reported by Rao 
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et al: among 24,112 subjects affected by ACS enrolled in 3 
international trials, 10% of patients underwent at least 1 blood 
transfusion during the hospitalization, and RBC transfusion 
was associated with an increased hazard for 30-day death 
and 30-day death/MI compared with patients who did not 
receive transfusions.46
Different results were obtained by Alexander et al who 
analyzed RBC transfusion policies and outcomes across 4 
distinct nadir Hct groups (Hct ≤24% vs. Hct 24.1%–27% 
vs. Hct 27.1%–30% vs. Hct>30%) in 44,242 patients with 
NSTEACS enrolled in the CRUSADE registry. RBC trans-
fusion had a favorable impact on in-hospital mortality in 
patients with a nadir Hct ≤24%, whereas higher mortality 
rates were observed among patients with Hct >30%. RBC 
transfusion in patients with intermediate Hct values did not 
have an impact on mortality.47
The picture seems slightly different when the impact of 
transfusion policies on outcome is analyzed in chronic heart 
failure patients. The systematic literature review conducted 
in 2013 by Kansagara et al, which included mainly patients 
with chronic heart failure, did not find consistent evidence 
that anemia correction improves outcomes.48
Results from clinical studies were incorporated in the 
most recently published guidelines concerning RBC transfu-
sion policies for critically ill patients, including those with 
cardiac disease.
The UK National Institute for Health and Care Excellence 
guideline on blood transfusion, published in November 2015, 
stated that the optimal transfusion threshold for patients with 
ongoing ACS should be 8–10 g/dL.49
Finally, the American Association of Blood Banks 
“Guidelines on RBC transfusion thresholds and storage” 
published in 201641 recommends a restrictive RBC transfu-
sion threshold for hospitalized, hemodynamically stable 
adult patients, including critically ill patients, orthopedic and 
cardiac surgery candidates and patients with preexisting car-
diovascular disease. However, these guidelines also state that 
the restrictive RBC transfusion threshold cannot be applied 
to ACS patients who are not hemodynamically stable, similar 
to the 2012 Cochrane review that also recommended the use 
of a restrictive transfusion trigger, but suggested caution in 
high-risk groups such as patients with ACS.50
Given the absence of solid evidence based on random-
ized controlled trials, it is probably reasonable to adopt RBC 
transfusion in patients with Hb levels <8 g/dL and to avoid it 
in patients with Hb levels >10 g/dL. Hb levels between 8 and 
10 g/dL still represent a “gray area” in which transfusion poli-
cies need to be tailored to a specific patient’s comorbidities, 
and may be based on the so-called physiologic transfusion 
triggers, which might potentially be used to replace arbitrary 
Hb-based transfusion triggers to estimate the limits of an 
individual patient’s tolerance to anemia.
Alternatives to RBC transfusion
As in other clinical settings, for example, chronic renal 
failure, anemia associated with chemotherapy, the use 
of iron and erythropoiesis-stimulating agents (ESAs) in 
patients with heart disease have been considered as means 
to potentially reverse anemia and overcome the need for 
RBC transfusions.
In studies on anemia associated with chronic heart fail-
ure,48 moderate-strength evidence suggests that intravenous 
iron supplements improve New York Heart Association 
(NYHA) class, exercise tolerance (6-minute walking dis-
tance), quality of life and cardiovascular events.51,52 However, 
results were similar in patients with Hb levels < and >12 g/
dL for the Patient Global Assessment (p-value for interaction 
with Hb level = 0.98), NYHA class (p-value for interaction 
= 0.51) and quality of-life (p-value for interaction = 0.59) 
outcomes. Moreover, in the setting of ACD, characterized by 
inhibition of iron absorption and reduction of iron mobiliza-
tion, the role of iron supplements is reasonably limited and 
questions its use in improving outcome in anemic patients. 
Iron supplements are not devoid of adverse effects. Some 
studies have linked iron administration with oxidative stress 
and immunomodulatory effects.53 Increased risk of infections 
has also been reported.54
In animal models, ESAs were shown to have cytoprotec-
tive effects, resulting in the reduction of cellular apoptosis 
and infarct size, and improvement in ejection fraction.55 
These results, however, were not confirmed in clinical stud-
ies, mainly involving patients with chronic heart failure. In 
this setting, there is high-strength evidence that ESA use 
has no beneficial effects on mortality, cardiovascular events 
and hospitalizations, while ESAs may be associated with 
hypertension, venous thromboembolism and even increased 
mortality.48
Further studies may clarify the role of ESAs in patients 
with preserved systolic function or in those with coronary 
heart disease only.
Conclusion and future prospects
Anemia is highly prevalent in the ACS setting and is associ-
ated with worse outcomes, particularly mortality. Current 
guidelines recommend correction of anemia <8 g/dL, 
except for hemodynamically unstable ACS patients who 
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could benefit from Hb levels between 8 and 10 g/dL. RBC 
transfusion is the only readily available treatment, but it is 
not a solution without complications. However, the question 
remains whether anemia has a direct causative role in worsen-
ing short- and long-term morbidity and mortality, or if it is 
rather a marker of a poor clinical condition.
In order to better understand the potential adverse impact 
of anemia per se, studies focused on selected groups of 
patients (STEACS vs. NSTEACS) and on specific Hb cut-
offs, rather than on generic anemia definitions, could improve 
our understanding of the still unresolved issue of the impact 
of anemia in patients with cardiac disease.
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